Manufacturer Roche Laboratories, Inc. should update Tamiflu labeling to include stronger warnings regarding the risk of psychiatric problems in users of the flu medicine, according to a U.S. Food and Drug Administration (FDA) committee. The FDA Pediatric Advisory Committee made its recommendations after evaluating reports of adverse events associated with use of the prescription influenza medication – including delusions, confusion, and self-injury – especially in children. The New York Times reports that “nearly 600 cases of psychiatric problems in Tamiflu patients have been reported, with 75 percent of them from Japan.”

  • FDA Information Page: Tamiflu
  • NY Times: Panel Seeks New Warning on Flu Drug
  • Tamiflu Side Effects and Safety (Roche Laboratories, Inc.)
  • Tamiflu Information and Resources (FindLaw)

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Civil Rights

Block on Trump’s Asylum Ban Upheld by Supreme Court

Criminal

Judges Can Release Secret Grand Jury Records

Politicians Can’t Block Voters on Facebook, Court Rules